Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HLA-A*02/NY-ESO-1 bispecific T-cell engager DS-2243a

A T-cell engaging bispecific antibody directed against the tumor-associated antigen (TAA) NY-ESO-1 complexed with human leukocyte antigen (HLA)-A*02 (HLA-A*02) and an antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-HLA-A*02/NY-ESO-1 bispecific T-cell engager DS-2243a targets and binds to an antigen found on cytotoxic T lymphocytes (CTLs) and NY-ESO-1 presented by HLA-A*02 expressed on tumor cells. This activates and redirects CTLs to NY-ESO-1-expressing tumor cells, which results in the CTL-mediated cell death of NY-ESO-1-expressing tumor cells. NY-ESO-1, a cell surface protein expressed in normal fetal and adult testes, is upregulated in a variety of tumor cell types as a HLA-A*02/NY-ESO-1 complex.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-NY-ESO-1 T-cell engaging bispecific antibody DS-2243a
bispecific T-cell engager anti-HLA-A*02/NY-ESO-1 DS-2243a
bispecific TCE DS-2243a
Code name:DS 2243
DS 2243a
DS-2243
DS-2243a
DS2243
DS2243a
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search